A Phase II Study of Oral Panobinostat (LBH589) and Rituximab to Treat Diffuse Large B Cell Lymphoma (DLBCL)
Status:
Unknown status
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to examine both efficacy of LBH589 in treating relapsed and
refractory DLBCL, and added benefit of combining rituximab with LBH589 in this setting.
Tissue samples from accessible lymph nodes will be collected and banked before the start of
the study treatment and after 15 days. Additionally, blood samples will be drawn and stored
in the tissue biobank.
Phase:
Phase 2
Details
Lead Sponsor:
Sarit Assouline
Collaborators:
Hoffmann-La Roche Novartis Quebec Clinical Research Organization in Cancer